Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Longitudinal trajectory of fatigue with initiation of biologic therapy in inflammatory bowel diseases: A prospective cohort study.

Borren NZ, Tan W, Colizzo FP, Luther J, Garber JJ, Khalili H, van der Woude CJ, Ananthakrishnan AN.

J Crohns Colitis. 2019 Aug 26. pii: jjz148. doi: 10.1093/ecco-jcc/jjz148. [Epub ahead of print]

PMID:
31504365
2.

Intra- and Inter-cellular Rewiring of the Human Colon during Ulcerative Colitis.

Smillie CS, Biton M, Ordovas-Montanes J, Sullivan KM, Burgin G, Graham DB, Herbst RH, Rogel N, Slyper M, Waldman J, Sud M, Andrews E, Velonias G, Haber AL, Jagadeesh K, Vickovic S, Yao J, Stevens C, Dionne D, Nguyen LT, Villani AC, Hofree M, Creasey EA, Huang H, Rozenblatt-Rosen O, Garber JJ, Khalili H, Desch AN, Daly MJ, Ananthakrishnan AN, Shalek AK, Xavier RJ, Regev A.

Cell. 2019 Jul 25;178(3):714-730.e22. doi: 10.1016/j.cell.2019.06.029.

PMID:
31348891
3.

A miniaturized, tethered, spectrally-encoded confocal endomicroscopy capsule.

Kang D, Do D, Ryu J, Grant CN, Giddings SL, Rosenberg M, Hesterberg PE, Yuan Q, Garber JJ, Katz AJ, Tearney GJ.

Lasers Surg Med. 2019 Jan 6. doi: 10.1002/lsm.23050. [Epub ahead of print]

PMID:
30614021
4.

Increased frequency of systemic pro-inflammatory Vδ1+ γδ T cells in HIV elite controllers correlates with gut viral load.

Olson GS, Moore SW, Richter JM, Garber JJ, Bowman BA, Rawlings CA, Flagg M, Corleis B, Kwon DS.

Sci Rep. 2018 Nov 7;8(1):16471. doi: 10.1038/s41598-018-34576-4.

5.

Second-Look Endoscopy in Hospitalized Severe Ulcerative Colitis: A Retrospective Cohort Study.

Borren NZ, Khalili H, Luther J, Colizzo FP, Garber JJ, Ananthakrishnan AN.

Inflamm Bowel Dis. 2019 Mar 14;25(4):750-755. doi: 10.1093/ibd/izy282.

PMID:
30204864
6.

Long-Term Outcomes of Immunosuppression-Naïve Steroid Responders Following Hospitalization for Ulcerative Colitis.

Vedamurthy A, Xu L, Luther J, Colizzo F, Garber JJ, Khalili H, Ananthakrishnan AN.

Dig Dis Sci. 2018 Oct;63(10):2740-2746. doi: 10.1007/s10620-018-5176-3. Epub 2018 Jun 27.

PMID:
29951797
7.

Model to Determine the Optimal Dietary Elimination Strategy for Treatment of Eosinophilic Esophagitis.

Zhan T, Ali A, Choi JG, Lee M, Leung J, Dellon ES, Garber JJ, Hur C.

Clin Gastroenterol Hepatol. 2018 Nov;16(11):1730-1737.e2. doi: 10.1016/j.cgh.2018.04.013. Epub 2018 May 3.

PMID:
29730438
8.

Genetic Markers Predict Primary Nonresponse and Durable Response to Anti-Tumor Necrosis Factor Therapy in Ulcerative Colitis.

Burke KE, Khalili H, Garber JJ, Haritunians T, McGovern DPB, Xavier RJ, Ananthakrishnan AN.

Inflamm Bowel Dis. 2018 Jul 12;24(8):1840-1848. doi: 10.1093/ibd/izy083.

9.

Attaching-and-Effacing Pathogens Exploit Junction Regulatory Activities of N-WASP and SNX9 to Disrupt the Intestinal Barrier.

Garber JJ, Mallick EM, Scanlon KM, Turner JR, Donnenberg MS, Leong JM, Snapper SB.

Cell Mol Gastroenterol Hepatol. 2017 Dec 15;5(3):273-288. doi: 10.1016/j.jcmgh.2017.11.015. eCollection 2018 Mar.

10.

Differences in Clinical Course, Genetics, and the Microbiome Between Familial and Sporadic Inflammatory Bowel Diseases.

Borren NZ, Conway G, Garber JJ, Khalili H, Budree S, Mallick H, Yajnik V, Xavier RJ, Ananthakrishnan AN.

J Crohns Colitis. 2018 Apr 27;12(5):525-531. doi: 10.1093/ecco-jcc/jjx154.

11.

Eosinophilic gastritis with involvement of esophageal gastric inlet patch.

Forcione DG, Lauwers GY, Garber JJ.

Gastrointest Endosc. 2018 May;87(5):1356-1358. doi: 10.1016/j.gie.2017.10.020. Epub 2017 Nov 3. No abstract available.

PMID:
29108982
12.

Clinical Predictors and Natural History of Disease Extension in Patients with Ulcerative Proctitis.

Walsh E, Chah YW, Chin SM, Lochhead P, Yajnik V, Denmark V, Garber JJ, Khalili H.

Inflamm Bowel Dis. 2017 Nov;23(11):2035-2041. doi: 10.1097/MIB.0000000000001214.

13.

Dietary Iron and Heme Iron Consumption, Genetic Susceptibility, and Risk of Crohn's Disease and Ulcerative Colitis.

Khalili H, de Silva PS, Ananthakrishnan AN, Lochhead P, Joshi A, Garber JJ, Richter JR, Sauk J, Chan AT.

Inflamm Bowel Dis. 2017 Jul;23(7):1088-1095. doi: 10.1097/MIB.0000000000001161. Review.

14.

Distance to Specialist Care and Disease Outcomes in Inflammatory Bowel Disease.

Borren NZ, Conway G, Tan W, Andrews E, Garber JJ, Yajnik V, Ananthakrishnan AN.

Inflamm Bowel Dis. 2017 Jul;23(7):1234-1239. doi: 10.1097/MIB.0000000000001133.

15.

Gut Microbiome Function Predicts Response to Anti-integrin Biologic Therapy in Inflammatory Bowel Diseases.

Ananthakrishnan AN, Luo C, Yajnik V, Khalili H, Garber JJ, Stevens BW, Cleland T, Xavier RJ.

Cell Host Microbe. 2017 May 10;21(5):603-610.e3. doi: 10.1016/j.chom.2017.04.010.

16.

ASPirin Intervention for the REDuction of colorectal cancer risk (ASPIRED): a study protocol for a randomized controlled trial.

Drew DA, Chin SM, Gilpin KK, Parziale M, Pond E, Schuck MM, Stewart K, Flagg M, Rawlings CA, Backman V, Carolan PJ, Chung DC, Colizzo FP 3rd, Freedman M, Gala M, Garber JJ, Huttenhower C, Kedrin D, Khalili H, Kwon DS, Markowitz SD, Milne GL, Nishioka NS, Richter JM, Roy HK, Staller K, Wang M, Chan AT.

Trials. 2017 Feb 1;18(1):50. doi: 10.1186/s13063-016-1744-z.

17.

The impact of co-existing immune-mediated diseases on phenotype and outcomes in inflammatory bowel diseases.

Conway G, Velonias G, Andrews E, Garber JJ, Yajnik V, Ananthakrishnan AN.

Aliment Pharmacol Ther. 2017 Mar;45(6):814-823. doi: 10.1111/apt.13940. Epub 2017 Jan 20.

18.

Older Age- and Health-related Quality of Life in Inflammatory Bowel Diseases.

Velonias G, Conway G, Andrews E, Garber JJ, Khalili H, Yajnik V, Ananthakrishnan AN.

Inflamm Bowel Dis. 2017 Feb;23(2):283-288. doi: 10.1097/MIB.0000000000001008.

19.

Identification and Characterization of a Novel Association between Dietary Potassium and Risk of Crohn's Disease and Ulcerative Colitis.

Khalili H, Malik S, Ananthakrishnan AN, Garber JJ, Higuchi LM, Joshi A, Peloquin J, Richter JM, Stewart KO, Curhan GC, Awasthi A, Yajnik V, Chan AT.

Front Immunol. 2016 Dec 7;7:554. doi: 10.3389/fimmu.2016.00554. eCollection 2016.

20.

Visceral Adiposity, Genetic Susceptibility, and Risk of Complications Among Individuals with Crohn's Disease.

Van Der Sloot KW, Joshi AD, Bellavance DR, Gilpin KK, Stewart KO, Lochhead P, Garber JJ, Giallourakis C, Yajnik V, Ananthakrishnan AN, Alizadeh BZ, Xavier RJ, Khalili H.

Inflamm Bowel Dis. 2017 Jan;23(1):82-88. doi: 10.1097/MIB.0000000000000978.

21.

Erratum to: Vedolizumab Therapy Is Associated with an Improvement in Sleep Quality and Mood in Inflammatory Bowel Diseases.

Stevens BW, Borren NZ, Velonias G, Conway G, Cleland T, Andrews E, Khalili H, Garber JJ, Xavier RJ, Yajnik V, Ananthakrishnan AN.

Dig Dis Sci. 2017 Feb;62(2):552. doi: 10.1007/s10620-016-4380-2. No abstract available.

PMID:
27864657
22.

Implementation and adherence to osteoporosis screening guidelines among coeliac disease patients.

Singh P, Garber JJ.

Dig Liver Dis. 2016 Dec;48(12):1451-1456. doi: 10.1016/j.dld.2016.08.121. Epub 2016 Sep 5.

PMID:
27665261
23.

Outcomes of Seropositive Patients With Marsh 1 Histology in Clinical Practice.

Singh P, Lauwers GY, Garber JJ.

J Clin Gastroenterol. 2016 Sep;50(8):619-23. doi: 10.1097/MCG.0000000000000522.

24.

Hepatic Injury in Nonalcoholic Steatohepatitis Contributes to Altered Intestinal Permeability.

Luther J, Garber JJ, Khalili H, Dave M, Bale SS, Jindal R, Motola DL, Luther S, Bohr S, Jeoung SW, Deshpande V, Singh G, Turner JR, Yarmush ML, Chung RT, Patel SJ.

Cell Mol Gastroenterol Hepatol. 2015 Mar;1(2):222-232.

25.

Body Mass Index, Genetic Susceptibility, and Risk of Complications Among Individuals with Crohn's Disease.

Pringle PL, Stewart KO, Peloquin JM, Sturgeon HC, Nguyen D, Sauk J, Garber JJ, Yajnik V, Ananthakrishnan AN, Chan AT, Xavier RJ, Khalili H.

Inflamm Bowel Dis. 2015 Oct;21(10):2304-2310. doi: 10.1097/MIB.0000000000000498.

26.

Mycobacterium chelonae bacteremia after first dose of infliximab for ulcerative colitis.

Kedrin D, Masia R, Nazarian RM, Garber JJ.

Am J Gastroenterol. 2014 Sep;109(9):1501-2. doi: 10.1038/ajg.2014.209. No abstract available.

27.

The ability of an attaching and effacing pathogen to trigger localized actin assembly contributes to virulence by promoting mucosal attachment.

Mallick EM, Garber JJ, Vanguri VK, Balasubramanian S, Blood T, Clark S, Vingadassalom D, Louissaint C, McCormick B, Snapper SB, Leong JM.

Cell Microbiol. 2014 Sep;16(9):1405-24. doi: 10.1111/cmi.12302. Epub 2014 Jun 2.

28.

Enteropathogenic Escherichia coli and vaccinia virus do not require the family of WASP-interacting proteins for pathogen-induced actin assembly.

Garber JJ, Takeshima F, Antón IM, Oyoshi MK, Lyubimova A, Kapoor A, Shibata T, Chen F, Alt FW, Geha RS, Leong JM, Snapper SB.

Infect Immun. 2012 Dec;80(12):4071-7. doi: 10.1128/IAI.06148-11. Epub 2012 Sep 10.

29.

Neural Wiskott-Aldrich syndrome protein modulates Wnt signaling and is required for hair follicle cycling in mice.

Lyubimova A, Garber JJ, Upadhyay G, Sharov A, Anastasoaie F, Yajnik V, Cotsarelis G, Dotto GP, Botchkarev V, Snapper SB.

J Clin Invest. 2010 Feb;120(2):446-56. doi: 10.1172/JCI36478. Epub 2010 Jan 11.

30.

Alcoholic hepatitis.

Martin WJ 2nd, Garber JJ.

Minn Med. 1975 Nov;58(11):816-9. No abstract available.

PMID:
1196275
31.

Alcoholic detoxification. A one-year experience.

Garber JJ, Dolander EV, Dexter JD.

Minn Med. 1974 Feb;57(2):143-5. No abstract available.

PMID:
4813613
32.

The chronic alcoholic in a small community hospital.

Garber JJ.

Minn Med. 1972 Jul;55(7):665-7. No abstract available.

PMID:
5064110
33.

Lupus erythematosus and hashimoto's thyroiditis.

Garber JJ, Worthington JW, Randall RV, Kierland RR.

Postgrad Med. 1969 Oct;46(4):100-5. No abstract available.

PMID:
5394925

Supplemental Content

Loading ...
Support Center